7.18
前日終値:
$7.00
開ける:
$7
24時間の取引高:
6.34M
Relative Volume:
1.31
時価総額:
$1.12B
収益:
$2.80M
当期純損益:
$-115.18M
株価収益率:
-8.474
EPS:
-0.8473
ネットキャッシュフロー:
$-94.03M
1週間 パフォーマンス:
+12.54%
1か月 パフォーマンス:
+39.96%
6か月 パフォーマンス:
+111.80%
1年 パフォーマンス:
+164.94%
Absci Corp Stock (ABSI) Company Profile
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABSI
Absci Corp
|
7.18 | 1.13B | 2.80M | -115.18M | -94.03M | -0.8473 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | 開始されました | JP Morgan | Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-01-22 | 開始されました | Needham | Buy |
| 2024-10-02 | 開始されました | Guggenheim | Buy |
| 2024-07-03 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2022-07-18 | 開始されました | Truist | Buy |
| 2022-03-02 | 再開されました | Cowen | Market Perform |
| 2022-02-01 | 開始されました | Berenberg | Buy |
| 2021-11-10 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-08-16 | 開始されました | BofA Securities | Neutral |
| 2021-08-16 | 開始されました | Cowen | Market Perform |
| 2021-08-16 | 開始されました | Credit Suisse | Outperform |
| 2021-08-16 | 開始されました | Stifel | Hold |
すべてを表示
Absci Corp (ABSI) 最新ニュース
Absci Corp stock hits 52-week high at 7.44 USD By Investing.com - Investing.com Australia
ABSI Maintains Buy Rating -- Price Target Raised to $15.00 by Gu - GuruFocus
Absci Corp (ABSI) awards RSUs and stock options to director Szela - Stock Titan
Absci Corp stock hits 52-week high at 7.44 USD - Investing.com
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ - marketscreener.com
Guggenheim raises Absci stock price target to $15 on hair loss drug - Investing.com Nigeria
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery - 01net
Absci Insiders Land Bargain With Gains Of US$1.4m - Moomoo
Can AI crack 'undruggable' drugs? MindWalk, Absci weigh in - Stock Titan
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates - MSN
Absci (ABSI) Q1 2026 Earnings Call Transcript - AOL.com
Absci (ABSI) director Karen McGinnis granted RSUs and stock options - Stock Titan
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
Absci (NASDAQ: ABSI) director Mary Szela awarded RSUs and stock options - Stock Titan
Absci (NASDAQ: ABSI) director granted RSUs and stock options in equity awards - Stock Titan
[Form 4] Absci Corp Insider Trading Activity - Stock Titan
Absci (NASDAQ: ABSI) awards director 10,100 RSUs and 39,800 options - Stock Titan
Absci (ABSI) director Joseph Sirosh awarded RSUs and 39,800-share option - Stock Titan
Absci (NASDAQ: ABSI) reports 2026 shareholder votes on directors and auditor - Stock Titan
Absci climbs after new outperform at Leerink on catalyst path - MSN
ABSI Initiates Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink Partners Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Absci Shares Rise After Leerink Partners Initiates Coverage at Outperform - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Absci stock granted New Outperform at Leerink (ABSI:NASDAQ) - Seeking Alpha
Absci Corp. Hits New 52-Week High of $7.33, Up 49.34% - MarketsMojo
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 - AOL.com
Absci Corp (ABSI) CFO reports 8,319-share tax withholding on RSU vesting - Stock Titan
ABSIAbsci Corp Stock Price and Quote - Finviz
Absci Corp. Stock Hits Day High with 17.83% Surge in Intraday Performance - Markets Mojo
ABSI News | ABSCI CORP (NASDAQ:ABSI) - ChartMill
BTIG Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $9 - Moomoo
This biotech is leading what could be a 'GLP-1 moment for hair loss,' says BTIG - CNBC
ABSI Initiates Coverage On BTIG -- Price Target Announced at $9. - GuruFocus
BTIG initiates Absci stock with buy rating on AI drug platform By Investing.com - Investing.com South Africa
BTIG initiates Absci stock with buy rating on AI drug platform - Investing.com Australia
This Suncrete Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026 - Investing.com Nigeria
Absci Insiders Placed Bullish Bets Worth US$1.22m - simplywall.st
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? - AOL.com
The 1 AI stock I'd put in a time capsule and open in 2036 - MSN
Grail's Slump Enters Week 10. Is There Any End in Sight? - AOL.com
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
2 Stocks That Could Realistically Double by 2030 - AOL.com
ABSI Price Today: Absci Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Absci Insider Buyers Pleased With US$700k Return On Investment - Yahoo Finance
Absci Corp (ABSI) 財務データ
収益
当期純利益
現金流量
EPS
Absci Corp (ABSI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
大文字化:
|
ボリューム (24 時間):